Unithroid Misappropriated Trade Secrets Claims Against FDA Reinstated
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal appeals court rules Jerome Stevens properly alleged an independent injury resulting from FDA’s disclosure of trade secrets and confidential information relating to the Unithroid (levothyroxine) NDA.
You may also be interested in...
Levothyroxine Bioequivalence To Be Discussed At FDA Public Meeting
Scheduling the event suggests FDA is re-evaluating its position on the interchangeability of the drug class. Announcement of the May 23 meeting comes nearly one year after the agency approved a number of equivalence claims for levothyroxine sodium products.
Endpoint Milestone In AML: Kronos’ Entospletinib Trial Will Rely On Residual Disease
Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: